|
🐜
|
Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts
17 auth.
L. Derikx,
Heather W Dolby,
N. Plevris,
L. Lucaciu,
C. Rees,
M. Lyons,
S. Siakavellas,
N. Constantine-Cooke,
P. Jenkinson,
Shanna Su,
...
C. O’Hare,
Laura Kirckpatrick,
L. Merchant,
C. Noble,
I. Arnott,
Gareth-Rhys Jones,
C. Lees
|
4 |
2021 |
4
🐜
|
|
🐜
|
Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis
7 auth.
L. Lucaciu,
N. Constantine-Cooke,
N. Plevris,
S. Siakavellas,
L. Derikx,
G. Jones,
...
C. Lees
|
4 |
2021 |
4
🐜
|
|
🐜
|
Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis
10 auth.
B. Gros,
Mairi Goodall,
N. Plevris,
N. Constantine-Cooke,
A. Elford,
C. O’Hare,
...
C. Noble,
G. Jones,
I. Arnott,
C. Lees
|
3 |
2023 |
3
🐜
|
|
🐜
|
Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
10 auth.
B. Gros,
N. Plevris,
N. Constantine-Cooke,
M. Lyons,
C. O’Hare,
C. Noble,
...
I. Arnott,
G. Jones,
C. Lees,
L. Derikx
|
3 |
2023 |
3
🐜
|
|
🐜
|
Real-world effectiveness of upadacitinib in Crohn’s disease: a UK multicentre retrospective cohort study
9 auth.
A. Elford,
M. Bishara,
N. Plevris,
B. Gros,
N. Constantine-Cooke,
J. Goodhand,
...
Nicholas A. Kennedy,
T. Ahmad,
C. Lees
|
3 |
2024 |
3
🐜
|
|
🐬
|
A review on competing risks methods for survival analysis
Karla Monterrubio-G'omez,
N. Constantine-Cooke,
C. A. Vallejos
|
2 |
2022 |
2
🐬
|
